文献速递其他结缔组织病

系统性硬化症治疗新视野:2025年进展与新兴疗法

New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025.
PubMed 文献 · RMD Open · 2025-07-01

本文综述系统性硬化症(SSc)按器官分层的现行治疗策略(皮肤、间质性肺病、肺动脉高压、硬皮病肾危象、雷诺现象与指端溃疡、胃肠道及肌肉骨骼受累)及新兴疗法;新兴疗法包括CD19靶向CAR-T细胞、双特异性抗体及靶向干扰素通路、BAFF、黑皮质素、FcRn和PDE4B的药物,反映向个体化、生物标志物驱动 approach 的转变。

要点

  • 传统免疫抑制治疗(吗替麦考酚酯、环磷酰胺、利妥昔单抗)仍是控制皮肤和肺部受累的基础。
  • 托珠单抗和尼达尼布在SSc相关间质性肺病中具有肺功能保护作用。
  • 肺动脉高压早期联合内皮素受体拮抗剂与磷酸二酯酶-5抑制剂,并联合塞来昔布和利奥西呱等新药。

核心结论

  • 新兴疗法体现向个体化和生物标志物驱动方法的转变,有望改变疾病轨迹并支持早期靶向干预。

研究设计与样本

  • 本文为综述,汇总当前SSc按器官分层的治疗策略及新兴疗法。

主要发现

  • 自体造血干细胞移植为部分高危患者提供经验证的疾病修饰选择。
  • 肺动脉高压早期联合内皮素受体拮抗剂与磷酸二酯酶-5抑制剂并联合塞来昔布和利奥西呱等新药,改善生存和生活质量。
  • 胃肠道、肾脏和肌肉骨骼管理持续演进,静脉注射免疫球蛋白和新型促动力药具前景。

临床怎么用

  • 传统免疫抑制治疗(吗替麦考酚酯、环磷酰胺、利妥昔单抗)仍是控制皮肤和肺部受累的关键。
  • 托珠单抗和尼达尼布在SSc相关间质性肺病中用于肺功能保护。
  • 肺动脉高压采用早期联合治疗(内皮素受体拮抗剂+磷酸二酯酶-5抑制剂),可加用塞来昔布和利奥西呱。
  • 静脉注射免疫球蛋白和新型促动力药在胃肠道、肾脏和肌肉骨骼管理中具前景。
  • 新兴疗法(CD19 CAR-T、双特异性抗体、干扰素通路/BAFF/黑皮质素/FcRn/PDE4B靶向药)反映个体化生物标志物驱动方向。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic sclerosis (SSc) is a rare, multisystem autoimmune disease characterised by vasculopathy, immune dysregulation, and progressive fibrosis, leading to significant morbidity and mortality. While recent EULAR recommendations have updated the standard of care for SSc, the field is rapidly evolving with novel therapeutic strategies and precision medicine approaches.Traditional immunosuppressive therapies-including mycophenolate mofetil, cyclophosphamide and rituximab-remain essential for controlling skin and lung involvement while autologous haematopoietic stem cell transplantation offers a proven disease-modifying option for selected high-risk patients. Tocilizumab and nintedanib have established roles in lung preservation in SSc-associated interstitial lung disease (SSc-ILD). In pulmonary arterial hypertension (PAH), early combination therapy with endothelin receptor antagonists and phosphodiesterase-5 inhibitors, complemented by newer agents such as selexipag and riociguat, has improved survival and quality of life. Advances in gastrointestinal, renal and musculoskeletal management continue to evolve, with promising roles for intravenous immunoglobulin and novel prokinetics.Crucially, emerging therapies-including CD19-targeted CAR-T cells, bispecific antibodies and agents targeting interferon pathways, BAFF, melanocortin, FcRn and PDE4B-reflect a shift towards personalised and biomarker-driven approaches. These innovations offer the potential to alter disease trajectory and support early, targeted intervention in SSc.This review provides an up-to-date synthesis of both current organ-based treatment strategies in major organ domains-skin, ILD, PAH, scleroderma renal crisis, raynaud's phenomenon and digital ulcers, gastrointestinal and musculoskeletal involvement-and emerging therapies in SSc, with an emphasis on disease-modifying approaches and future directions in personalised care.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Sieiro Santos C, Del Galdo F. New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025. RMD Open. 2025. PMID: 40592721. doi:10.1136/rmdopen-2025-005776

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。